Literature DB >> 1279852

The spectrum of cystic fibrosis mutations.

L C Tsui1.   

Abstract

Although the major mutation causing cystic fibrosis accounts for almost 70% of mutant chromosomes screened, almost 300 sequence alterations have been identified in the gene during the past two and a half years. At least 230 of these mutations are probably associated with disease. This rapid accumulation of data is in part due to the highly coordinated effort by members of the Cystic Fibrosis Genetic Analysis Consortium. The information is not only essential to genetic diagnosis, but also will aid in understanding the structure and function of the protein, and possibly in correlating genotype with phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279852     DOI: 10.1016/0168-9525(92)90301-j

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  95 in total

1.  Mutation detection by stacking hybridization on genosensor arrays.

Authors:  R Maldonado-Rodriguez; M Espinosa-Lara; P Loyola-Abitia; W G Beattie; K L Beattie
Journal:  Mol Biotechnol       Date:  1999-02       Impact factor: 2.695

Review 2.  Cystic fibrosis--an Indian perspective on recent advances in diagnosis and management.

Authors:  S K Kabra; M Kabra; M Ghosh; I C Verma
Journal:  Indian J Pediatr       Date:  1996 Mar-Apr       Impact factor: 1.967

3.  What happens to deltaF508 in vivo?

Authors:  M Drumm
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

4.  Attitudes of high school students toward carrier screening and prenatal diagnosis of cystic fibrosis.

Authors:  Sharon J Durfy; Andrea Page; Barry Eng; Patricia L Chang; John S Waye
Journal:  J Genet Couns       Date:  1994-06       Impact factor: 2.537

5.  Scientific limitations and ethical ramifications of a non-representative Human Genome Project: African American response.

Authors:  Fatimah Jackson
Journal:  Sci Eng Ethics       Date:  1998-04       Impact factor: 3.525

6.  Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis.

Authors:  M Srivastava; O Eidelman; H B Pollard
Journal:  Mol Med       Date:  1999-11       Impact factor: 6.354

Review 7.  Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.

Authors:  Peter Sazani; Ryszard Kole
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

8.  Delta F508 CFTR pool in the endoplasmic reticulum is increased by calnexin overexpression.

Authors:  Tsukasa Okiyoneda; Kazutsune Harada; Motohiro Takeya; Kaori Yamahira; Ikuo Wada; Tsuyoshi Shuto; Mary Ann Suico; Yasuaki Hashimoto; Hirofumi Kai
Journal:  Mol Biol Cell       Date:  2003-10-31       Impact factor: 4.138

9.  How is the Human Genome Project doing, and what have we learned so far?

Authors:  M S Guyer; F S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Identification of the M1101K mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and complete detection of cystic fibrosis mutations in the Hutterite population.

Authors:  J Zielenski; T M Fujiwara; D Markiewicz; A J Paradis; A I Anacleto; B Richards; R H Schwartz; K W Klinger; L C Tsui; K Morgan
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.